30 closest matches · ranked by relevance
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
Healthy
Primary: Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration — 4.79; 12.83; 11.08; 12.17 units on a scale
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Alcohol Drinking · Opioid Use
Primary: Alcohol Use Reductions — 11; 12; 1; 1 Participants
Medication Abuse
Primary: Percentage of PDMP Checks Conducted During High-risk Prescriptions — 8187; 6322; 13360; 23328 health care encounters
Substance-Related Disorders
Primary: Number of Participants With Drug Use at 3 Months — 49; 48 participants
Lumbar Disc Degenerative Disease
Primary: Overall Satisfaction Degree After 2 Weeks Treatment of Triple Therapy (MBL+MYO+NSAID). — 91.21; 7.74; 1.05; 86.4 percentage of participants
Addiction
Primary: Receipt of Brief Intervention (BI) for Drug Use at Baseline Visit — 17; 33 Participants
Methamphetamine · Alcohol
Primary: Feasibility of Retaining Participants in Trial — 100; 86.7 percentage that completed study
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Polypharmacy · Surgical Procedure, Operative · Morality
Primary: Mortality — 4356; 1919 Participants
Diabetes · Hypertension
Primary: Measure of Medication Self-Management (MeDS) — 10.9; 2.5 units on a scale — p=<.001
Polypharmacy · Dementia · Multiple Chronic Conditions
Primary: Preliminary Efficacy of the Intervention to be Assessed From Primary Care Clinician's Intervention Visit Clinical Notes and EHR — 15; 7; 7; 7 Participants
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
Staphylococcal Infections
Primary: Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert. — 1; 1; 1; 1 participants
Feedback, Psychological · Clinical Trial · Substance Abuse
Primary: Change in Past 6 Month Non-Medical Use of Prescription Stimulant Medication Frequency — -2.04; -1.72; -1.03; -.38 Usage days — p=0.03
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Adherence
Primary: Medication Adherence - Pill Count — 0.46; 0.53 Probability of adherence (PT/PP => 0.8) — p=0.04
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
Alcohol or Other Drugs Use
Primary: Mean Number of Days Used Primary Drug (NumDU) — 8.5; 5.0 days
Stimulant Use
Primary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8…
Cannabis-use Disorders
Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…
Drug Use · Alcohol Use · Congestive Heart Failure
Primary: Change in Substance Use Rates From Baseline — 51.37; 51.38; 35.53; 26.65 Days of Substance Use
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Alcohol Use Disorder · Bipolar Disorder · Schizoaffective Disorder Bipolar Type
Primary: Baseline-to-Exit Change in Drinks Per Drinking Day (TLFB) — -1.98; -2.82; -1.22 Standard Drinks per Drinking Day
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters